Repatha (Evolocumab) Dosing for Adults 65 and Older

No Dose Adjustment Is Needed After Age 65

Evolocumab dosing remains the same for patients 65 and older as it does for younger adults. The FDA-approved prescribing information specifies two regimens: 140 mg administered subcutaneously every two weeks, or 420 mg administered subcutaneously once monthly [1]. Neither regimen requires modification based on age alone.

This consistency stems from the drug's pharmacokinetic profile. Evolocumab is a fully human monoclonal antibody (IgG2) that binds proprotein convertase subtilisin/kexin type 9 (PCSK9). Unlike small-molecule statins metabolized through hepatic cytochrome P450 enzymes, monoclonal antibodies undergo proteolytic degradation into amino acids through the reticuloendothelial system [2]. Age-related changes in hepatic enzyme activity and renal filtration have minimal impact on this catabolic pathway. Population pharmacokinetic analyses submitted to the FDA showed no clinically meaningful differences in evolocumab exposure between patients younger than 65, those aged 65 to 74, and those 75 and older [1].

The Endocrine Society's 2020 clinical practice guideline on lipid management supports PCSK9 inhibitor use in older adults with atherosclerotic cardiovascular disease (ASCVD) who have not reached LDL-C targets on maximally tolerated statin therapy, without specifying age-based dose modifications [3]. The absence of dose titration simplifies prescribing for clinicians managing older patients who may already be navigating complex medication regimens.

FOURIER Trial Results in Older Adults

The FOURIER trial (Further Cardiovascular Outcomes Research with PCSK9 Inhibition in Subjects with Elevated Risk) randomized 27,564 patients with established ASCVD to evolocumab or placebo on top of statin therapy [4]. Of these, 8,456 were aged 65 or older, and 2,747 were 75 or older, making this one of the largest PCSK9 inhibitor datasets in a geriatric population.

Across the entire cohort, evolocumab reduced LDL-C by a median of 59% from baseline (from 92 mg/dL to 30 mg/dL) at 48 weeks. The primary composite endpoint of cardiovascular death, myocardial infarction, stroke, hospitalization for unstable angina, or coronary revascularization decreased by 15% (hazard ratio 0.85, 95% CI 0.79-0.92, P<0.001) [4].

A prespecified age-stratified subgroup analysis published in The Lancet demonstrated that the relative risk reduction was consistent in patients aged 65 to 74 (HR 0.82) and those 75 and older (HR 0.74) compared with patients younger than 65 (HR 0.86), with no significant interaction by age (P-interaction = 0.60) [5]. Because baseline cardiovascular event rates are higher in older adults, the absolute risk reduction was numerically larger. For every 1,000 patients aged 75+ treated for 3 years, approximately 23 major cardiovascular events were prevented, compared with 16 per 1,000 in younger patients.

Dr. Robert Giugliano, the FOURIER co-principal investigator from Brigham and Women's Hospital, noted: "Older patients derived at least as much benefit from evolocumab as younger patients, and possibly more on an absolute basis, because their underlying event rates are higher" [5].

Renal Function and Evolocumab Clearance

Declining glomerular filtration rate is nearly universal in patients over 65, raising reasonable questions about drug clearance. For evolocumab, the answer is straightforward: renal function does not affect dosing.

Monoclonal antibodies with molecular weights around 144 kDa are too large to undergo glomerular filtration. Evolocumab's molecular weight of approximately 144 kDa means intact antibody molecules do not pass through the glomerular basement membrane in clinically meaningful quantities [2]. The kidneys contribute negligibly to its elimination.

Amgen's population pharmacokinetic analysis included patients with mild (eGFR 60-89 mL/min/1.73 m²) and moderate (eGFR 30-59 mL/min/1.73 m²) renal impairment. No dose adjustment was required in either group [1]. Data in severe renal impairment (eGFR <30 mL/min/1.73 m²) are limited, but the mechanism of elimination predicts minimal impact. A 2019 post-hoc FOURIER analysis confirmed that evolocumab's LDL-C-lowering efficacy and safety profile remained consistent across renal function categories [6].

For clinicians accustomed to adjusting renally cleared medications in geriatric patients, evolocumab represents one fewer variable to calculate. No creatinine clearance estimation, no dose reduction table, no interval extension.

Polypharmacy and Drug Interaction Considerations

Adults aged 65 and older take a median of five prescription medications in the United States, according to CDC National Health and Nutrition Examination Survey data [7]. Each additional drug increases the probability of clinically significant interactions.

Evolocumab carries no known drug-drug interactions listed in its prescribing information [1]. As a monoclonal antibody, it does not interact with cytochrome P450 enzymes, P-glycoprotein transporters, or organic anion transport systems. It does not alter the pharmacokinetics of statins, ezetimibe, warfarin, or any other cardiovascular medication.

This pharmacologic independence makes evolocumab particularly practical for older patients on combination regimens. A patient taking atorvastatin, metoprolol, lisinopril, aspirin, and metformin can add evolocumab without adjusting any existing medication or monitoring for new interactions.

One caveat deserves attention. While evolocumab itself does not interact with other drugs, it is typically prescribed alongside high-intensity statin therapy. The statin component of the regimen does carry interaction potential, particularly with certain calcium channel blockers (amlodipine, diltiazem), macrolide antibiotics, and antifungal agents [8]. Clinicians should continue to monitor statin-related interactions independently of the PCSK9 inhibitor.

Injection Technique and Dexterity in Older Patients

Three delivery devices exist for evolocumab: the prefilled syringe, the SureClick autoinjector, and the Pushtronex on-body infusor (for the 420 mg monthly dose). Device selection for geriatric patients should account for manual dexterity, visual acuity, and cognitive function.

The SureClick autoinjector requires less fine motor control than the manual syringe. Patients press the device against the skin and click a button. Spring-loaded injection takes approximately 15 seconds. For patients with arthritis affecting grip strength, the autoinjector's broader grip surface and push-button mechanism may reduce injection difficulty [9].

The Pushtronex on-body infusor delivers the 420 mg dose (three 140 mg cartridges loaded into one device) over approximately 5 minutes. Patients apply it to the abdomen, press start, and leave it in place. This device suits patients who prefer monthly dosing but find multiple syringe injections burdensome.

A practical consideration for patients living alone: the abdomen is the easiest self-injection site. The upper arm, while approved, requires either a caregiver or considerable flexibility to access. Rotating injection sites within the abdomen (at least 2 inches from the navel, avoiding areas that are tender, bruised, or scarred) reduces the risk of lipodystrophy over time [1].

Patients or caregivers should remove the device from refrigeration 30 minutes before injection. Cold injections cause more discomfort. The medication may also be stored at room temperature (up to 25°C / 77°F) for up to 30 days, which may simplify storage for patients with limited refrigerator space or those traveling [1].

Deprescribing Context: When PCSK9 Inhibitors Fit and When They May Not

Not every patient over 65 with elevated LDL-C is a candidate for adding another injectable medication. Deprescribing frameworks, including the American Geriatrics Society Beers Criteria and the STOPPFrail guidelines, encourage clinicians to evaluate whether each medication's expected benefit exceeds its burden within the patient's remaining life expectancy and functional trajectory [10].

Evolocumab's cardiovascular benefit in FOURIER emerged within 12 months for the secondary endpoint (cardiovascular death, MI, or stroke), though the primary endpoint separation grew over the full 2.2-year median follow-up [4]. For patients with established ASCVD, reasonable functional status, and a life expectancy exceeding 2 years, the evidence supports initiation or continuation.

For patients in the final stages of life, those with advanced dementia who cannot participate in injection decisions, or those whose primary treatment goal has shifted entirely to comfort, the biweekly or monthly injection schedule may represent an unwelcome burden. A shared decision between the prescribing clinician, the patient (when capable), and caregivers is appropriate.

The 2018 ACC/AHA cholesterol guideline recommends a clinician-patient risk discussion before initiating PCSK9 inhibitors, considering cost, injection burden, and patient preference alongside the expected magnitude of LDL-C reduction and ASCVD risk lowering [11].

Monitoring After Initiation

Check a fasting lipid panel 4 to 8 weeks after starting evolocumab to confirm LDL-C response [11]. Most patients achieve 50-60% LDL-C reduction from pre-treatment baseline. If the response is substantially lower, assess adherence (missed injections are the most common cause of suboptimal response) and confirm proper injection technique and storage.

Routine liver function testing is not required for evolocumab. Unlike statins, PCSK9 inhibitors do not carry hepatotoxicity signals in clinical trial data [4]. Similarly, creatine kinase monitoring for myopathy is unnecessary for the PCSK9 inhibitor itself, though it remains relevant if the patient is on concurrent statin therapy.

Evolocumab has been associated with injection-site reactions (erythema, pain, bruising) in 3.2% of patients in FOURIER, comparable to placebo injection-site reaction rates of 3.0% [4]. Neurocognitive events were tracked prospectively in the EBBINGHAUS substudy (N=1,974), which found no difference in cognitive function between evolocumab and placebo groups over a median of 19 months using the Cambridge Neuropsychological Test Automated Battery [12]. This finding is relevant for geriatric patients and their families who may express concern about very low LDL-C levels and brain health.

Dr. Robert Giugliano, also the EBBINGHAUS principal investigator, stated: "We found no signal for adverse neurocognitive effects, even among patients who achieved LDL-C levels below 25 mg/dL" [12].

Practical Prescribing Steps for the Geriatric Patient

Starting a geriatric patient on evolocumab follows the same prescribing pathway as for younger adults, with a few practical additions:

1. Confirm the patient has ASCVD or heterozygous/homozygous familial hypercholesterolemia (HeFH/HoFH) and remains above their LDL-C goal on maximally tolerated statin therapy (with or without ezetimibe).
2. Assess the patient's ability to self-inject or identify a caregiver who can administer injections on the prescribed schedule.
3. Select the device format: autoinjector for most self-injecting patients, on-body infusor for monthly dosing preference, manual syringe only if the patient or caregiver is comfortable with the technique.
4. Verify insurance coverage and initiate prior authorization. Amgen's patient support program may provide copay assistance for commercially insured patients. Medicare Part D coverage varies by plan.
5. Prescribe 140 mg subcutaneously every 2 weeks or 420 mg subcutaneously once monthly. No dose adjustment for age, weight, renal function, or hepatic function.
6. Schedule follow-up lipid panel at 4 to 8 weeks.
7. Reassess annually whether the patient's clinical trajectory, functional status, and goals of care continue to support ongoing therapy.

The 420 mg monthly dose is bioequivalent to the 140 mg biweekly dose in steady-state LDL-C reduction [1]. Choose based on patient preference for injection frequency.